© 1999 by European Society of Cardiology
Determinants of development of permanent atrial fibrillation and its treatment
aArrhythmologic Center Ospedali Riuniti, Lavagna; bArrhythmologic Center Ospedale S Maria Nuova, Reggio Emilia, Italy
We evaluated the rate of progression of permanent atrial fibrillation (AF) and identified clinical factors that predict this event in 63 consecutive patients who had undergone AV junctional ablation and DDDR pacemaker implantation for drug-refractory paroxysmal atrial fibrillation/flutter. Immediately after ablation, anti-arrhythmic drugs were discontinued in all cases. Permanent AF was con-sidered to have developed if AF was present on two consecutive 6-monthly examinations with no interim documented sinus rhythm. During a mean follow-up of 23±16 months, 22 (35%) of the 63 patients developed permanent AF. The actuarial estimate of progression of permanent AF was 22%, 40% and 56%, respectively, 1, 2 and 3 years after ablation. Age and underlying heart disease were independent predictors of progression of permanent AF. Only one (6%) of 16 patients with idiopathic AF had permanent AF (low risk group). Among the 47 patients with structural heart disease, permanent AF developed in 18 (62%) of the 29 who were aged >75 years or had >12 arrhythmic episodes per year and a symptom duration >4 years (high risk group), but only in three (17%) of the remaining 18 patients who did not (intermediate risk group). In conclusion, during a 3-year follow-up period, about half of the patients with a history of drug-refractory paroxysmal AF did not develop permanent AF after AV junctional ablation and dual-chamber pacemaker implantation, even in the absence of anti-arrhythmic drug therapy. Moreover, subgroups of patients whose risk of permanent AF progression differed were identified on the basis of simple baseline clinical variables. The results of this study form the necessary background for the correct management of patients after AV junction ablation and for the planning of future trials in this field.
Key Words: Catheter ablation, dual-chamber pacemaker, paroxysmal atrial fibrillation, natural history of atrial fibrillation, atrioventricular junctional ablation
Correspondence: Michele Brignole, MD, Via A Grilli 164, 16041 Borzonasca (GE), Italy.
[1] Jensen SM, Bergfeldt L, Rosenquist M. Long-term follow-up of patients treated by radiofrequency ablation of the atrioventricular junction. PACE 1995; 18: 1609–1614.
[2] Fitzpatrick AD, Kourouyan HD, Siu A, et al. Quality of life and outcomes after radiofrequency His-bundle catheter ablation and permanent pacemaker implantation: impact of treatment in paroxysmal and established atrial fibrillation. Am Heart J 1996; 131: 499–507.[CrossRef][Web of Science][Medline]
[3] Brignole M, Gianfranchi L, Menozzi C, et al. An assessment of atrioventricular junction ablation and DDDR mode-switching pacemaker versus pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation. A randomized controlled study. Circulation 1997; 96: 2617–2624.
[4] Takahashi N, Seki A, Imataka K, Fujii J. Clinical features of paroxysmal atrial fibrillation: an observation of 94 patients. Jpn Heart J 1981; 22: 143–149.[Medline]
[5] Mitchell MA, Ackerman SJ, Nath S, Haines D, DiMarco JP. Atrial rhythm after atrioventricular junctional ablation. Am J Cardiol 1996; 78: 1251–1254.[CrossRef][Web of Science][Medline]
[6] Gribbin GM, Bourke JP, McComb J. Dual versus single chamber pacemakers in patients with paroxysmal atrial fibrillation treated with AV node ablation (Abstr). PACE 1997; 20: 1592.
[7] Sgarbossa E, Pinski S, Maloney JD, et al. Chronic atrial fibrillation and stroke in paced patients with sick sinus syndrome. Circulation 1993; 88: 1045–1053.
[8] Andersen HR, Thuesen L, Bagger JP, Vesterlund T, Thomsen BEB. Prospective randomized trial of atrial versus ventricular pacing in sick sinus syndrome. Lancet 1994; 334: 1523–1528.
[9] Connolly SJ, Kerr C, Gent M, Yusuf S. Dual-chamber versus ventricular pacing. Critical appraisal of current data. Circulation 1996; 94: 578–583.
[10] Rostagno C, Bacci F, Martelli M, Naldoni A, Bertini G, Gensini G. Clinical course of lone atrial fibrillation since first symtomatic arrhythmic episode. Am J Cardiol 1995; 76: 837–839.[CrossRef][Web of Science][Medline]
[11] Scardi S, Ceschia G, Pandullo C, Benettoni A, Pivotti F. Natural history of patients with isolated atrial fibrillation. G Ital Cardiol 1987; 17: 492–497.[Medline]
[12] Crjins HJ, Van Gelder IC, Van Gilst WH, Hillege H, Gosselink AM, Lie KI. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. Am J Cardiol 1991; 68: 335–341.[CrossRef][Web of Science][Medline]
[13] Sakamoto H, Okamoto E, Imataka K, Ieki K, Fujii J. Prediction of early development of chronic nonrheumatic atrial fibrillation. Jpn Heart J 1995; 36: 191–199.[Medline]
[14] Lamas GA, Pashos CL, Normand SL, McNeil B. Permanent pacemaker selection and subsequent survival in elderly Medicare pacemaker recipients. Circulation 1995; 91: 1063–1069.
[15] Brignole M. on behalf of the PAF II study investigators. The outcome after ablation and pacing for paroxysmal atrial fibrillation: the effect of antiarrhythmic drugs on maintenance of normal sinus rhythm and on quality of life. The study design (in press).
[16] Prystowsky E, Benson DW, Fuster V, et al. Management of patients with atrial fibrillation. A statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation 1996; 93: 1262–1277.[Medline]
[17] The Planning and Steering Committees of the AFFIRM Study for the NHLBI AFFIRM Investigators. Atrial fibrillation follow-up. Investigation of rhythm management. The AFFIRM study design. Am J Cardiol 1997; 79: 1198–1202.[CrossRef][Web of Science][Medline]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A Queiroga, H J Marshall, M Clune, and M D Gammage Ablate and pace revisited: long term survival and predictors of permanent atrial fibrillation Heart, September 1, 2003; 89(9): 1035 - 1038. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Brignole, M. Gammage, L. Jordaens, R. Sutton, and on behalf of the Barcelona Discussion Group Report of a study group on ablate and pace therapy for paroxysmal atrial fibrillation Europace, January 1, 1999; 1(1): 8 - 13. [Abstract] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||